THLD » Topics » NOTE 1-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This excerpt taken from the THLD 10-K filed Mar 13, 2009.

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

STYLE="margin-top:6px;margin-bottom:0px; text-indent:2%">Description of Operations and Basis of Presentation

FACE="Times New Roman" SIZE="2">Threshold Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on October 17, 2001. The Company is a biotechnology company focused on the discovery and development of drugs
targeting the microenvironment of solid tumors.

In June 2005, the Company formed a wholly-owned subsidiary, THLD Enterprises (UK), Limited
in the United Kingdom in connection with conducting clinical trials in Europe. As of December 31, 2008, there has been no financial activity related to this entity.

FACE="Times New Roman" SIZE="2">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include the accounts of the Company and its wholly
owned subsidiary, and reflect the elimination of intercompany accounts and transactions.

This excerpt taken from the THLD 10-K filed Mar 12, 2008.

NOTE 1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

STYLE="margin-top:6px;margin-bottom:0px; text-indent:2%">Description of Operations and Basis of Presentation

FACE="Times New Roman" SIZE="2">Threshold Pharmaceuticals, Inc. (the “Company”) was incorporated in the State of Delaware on October 17, 2001. The Company is a biotechnology company focused on the discovery and development of drugs
targeting the microenvironment of solid tumors.

In June 2005, the Company formed a wholly-owned subsidiary, THLD Enterprises (UK), Limited
in the United Kingdom in connection with conducting clinical trials in Europe. As of December 31, 2007, there has been no financial activity related to this entity.

FACE="Times New Roman" SIZE="2">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include the accounts of the Company and its wholly
owned subsidiary, and reflect the elimination of intercompany accounts and transactions.

EXCERPTS ON THIS PAGE:

10-K
Mar 13, 2009
10-K
Mar 12, 2008

"NOTE 1-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" elsewhere:

ABAXIS (ABAX)
ArQule (ARQL)
Immunomedics (IMMU)
Monogram Biosciences (MGRM)
Neogen (NEOG)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki